TD Cowen Begins Coverage on Johnson & Johnson (NYSE:JNJ)

Research analysts at TD Cowen initiated coverage on shares of Johnson & Johnson (NYSE:JNJ) in a research report issued on Wednesday, MarketBeat reports. The firm set a “buy” rating and a $250.00 price target on the stock. TD Cowen’s price target indicates a potential upside of 3.68% from the stock’s current price.

Other research analysts have also recently issued reports about the company. Loop Capital set a $220.00 price objective on Johnson & Johnson in a report on Tuesday, January 27th. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Wolfe Research lifted their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a report on Monday, January 5th. Citigroup lifted their price objective on Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wells Fargo & Company lifted their price objective on Johnson & Johnson from $230.00 to $240.00 and gave the company an “overweight” rating in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $237.57.

Johnson & Johnson Stock Down 0.1%

Shares of JNJ stock opened at $241.13 on Wednesday. The stock has a market cap of $580.78 billion, a P/E ratio of 21.82, a price-to-earnings-growth ratio of 2.39 and a beta of 0.34. Johnson & Johnson has a one year low of $145.13 and a one year high of $251.71. The stock has a fifty day moving average price of $241.07 and a 200 day moving average price of $214.54. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The firm had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Insider Transactions at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 30,142 shares of company stock valued at $7,360,528 over the last ninety days. 0.16% of the stock is currently owned by company insiders.

Institutional Trading of Johnson & Johnson

A number of hedge funds have recently modified their holdings of JNJ. AustralianSuper Pty Ltd raised its stake in Johnson & Johnson by 632.0% in the 3rd quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company’s stock valued at $16,536,000 after acquiring an additional 77,000 shares during the period. J.W. Cole Advisors Inc. raised its stake in Johnson & Johnson by 2.2% in the 3rd quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company’s stock valued at $24,278,000 after acquiring an additional 2,769 shares during the period. Guinness Asset Management LTD raised its stake in Johnson & Johnson by 0.4% in the 3rd quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company’s stock valued at $251,216,000 after acquiring an additional 5,994 shares during the period. Treasurer of the State of North Carolina raised its stake in Johnson & Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after acquiring an additional 94,957 shares during the period. Finally, National Pension Service raised its stake in Johnson & Johnson by 3.2% in the 3rd quarter. National Pension Service now owns 4,926,569 shares of the company’s stock valued at $913,484,000 after acquiring an additional 151,707 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: TD Cowen reiterated a Buy and set a $250 price target, underpinning near-term upside expectations from improving fundamentals and pipeline momentum. TD Cowen Buy, $250 PT
• Positive Sentiment: Citi and other brokers have raised price targets and highlighted J&J’s stronger MedTech outlook, supporting bullish analyst sentiment that could prop the shares if Q1 confirms recovery. Citigroup Forecasts Strong Price Appreciation for JNJ
• Positive Sentiment: J&J launched the VARIPULSE Pro pulsed field ablation system in Europe (CE mark), adding a potential growth driver for its MedTech segment as real‑world studies and conference data are collected. This rollout is a concrete revenue catalyst if adoption scales. Johnson & Johnson PFA Launch Puts VARIPULSE Pro And Valuation In Focus
• Neutral Sentiment: Coverage pieces in Barron’s and TipRanks emphasize the rebound narrative heading into earnings, raising visibility but not adding new fundamental proof — they may support sentiment but won’t move the stock without data. Buy Johnson & Johnson Ahead of Earnings
• Neutral Sentiment: Market / media mentions (lists, S&P visibility) and multiple analyst notes increase attention; these can amplify moves but are secondary to earnings and device adoption. JNJ Gains Visibility As S&P 500 Trends Shift
• Negative Sentiment: Zacks warns that rising biosimilar competition and pricing pressure remain material headwinds for J&J’s pharma business; those risks mean the upcoming Q1 print could produce downside if guidance or growth details disappoint. Should You Buy, Sell or Hold JNJ Ahead of Q1
• Negative Sentiment: Upcoming Q1 estimates and metric expectations introduce short‑term volatility: if reported drug growth or MedTech momentum falls short of elevated analyst hopes, the stock could underperform. Wall Street Estimates for JNJ Q1

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.